CardioDx Expands Patient Access to the Corus(R) CAD Test

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CardioDx Expands Patient Access to the Corus(R) CAD Test Through National Agreement With Quest Diagnostics

REDWOOD CITY, CA--(Marketwired - Sep 16, 2015) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics ( NYSE : DGX ), the world's leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD)*.

Under a multi-year agreement, clinicians will be able to order blood draws on patients for testing through Quest's approximately 2,200 patient service centers and 4,000 phlebotomists in physician offices in the United States. Samples will be forwarded to CardioDx's CLIA-certified laboratory (in Redwood City, Calif.) for testing. 

"This agreement will expand patient access to the Corus CAD test, a test that complements Quest's suite of advanced diagnostic information services for assessing risk of cardiovascular disease and personalizing treatment," said Patrick Plewman, General Manager of Quest Diagnostics Cardiovascular, Metabolic and Endocrinology Clinical Franchise. "The addition of this test to our offering provides a new avenue to generate value from Quest's uniquely large network of patient service centers and in-office phlebotomists in the United States." 

"Following coverage of the Corus CAD test from Aetna and Coventry Health, this agreement with Quest represents another major milestone that will expand patient access to the test and allow CardioDx to strengthen relationships with clinicians," said David Levison, President and Chief Executive Officer of CardioDx. "Quest is the world leader in diagnostic testing, and we are thrilled that it will now be easier for patients to access the Corus CAD test."

CAD is the most common form of heart disease and is responsible for one in seven deaths in the United States. 1  Diagnosis typically involves medical imaging or invasive procedures in which a catheter is inserted in an artery or vein in your groin, neck or arm and threaded through a person's blood vessel to visualize the heart arteries. 

The Corus CAD test is the first and only commercially available blood-based test that provides a current-state assessment of obstructive CAD. With a 96% negative predictive value, 2 the test incorporates age, sex, and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Combined with other clinical information, the test can help clinicians quickly, accurately, and safely determine if a patient's symptoms are caused by obstructive CAD. 

Used early in the evaluation of symptomatic patients, the test can help clinicians determine whether or not further cardiac testing is necessary, thus helping patients avoid unnecessary noninvasive imaging and invasive cardiac procedures that are often more complex, expensive and expose patients to significant amounts of radiation and other adverse risks. Patients with low Corus CAD test scores had a statistically significant 82% decreased odds of referral for further cardiac evaluation or testing in a recently published study of 718 nonacute patients receiving the Corus CAD test in the primary care setting. 3  

"As concerns about radiation exposure and test overutilization continue to grow within the medical community, the Corus CAD test is well positioned to address the need for solutions that minimize risk and help streamline clinical decision-making," added Mark Monane, M.D., Chief Medical Officer. "Quest has been at the forefront of adopting innovative diagnostic solutions that can help improve human health. We are proud to collaborate with them to help make the Corus CAD test available to more clinicians and patients across the country."

Separately, CardioDx's commercial operation continues to expand with a new $20 million round of financing from Solar Capital Ltd. and Silicon Valley Bank as well as current investors. The financing was facilitated by Armentum Partners.

About Obstructive Coronary Artery Disease Coronary artery disease (CAD) is a very common heart condition in the United States. CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque.

About the Corus CAD Test Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac tests requiring catheterization. The test involves a routine blood draw that is conveniently administered in the clinician's office or clinical laboratory patient service center. The Corus CAD test is the only sex-specific test for the evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women.

The test has been clinically validated in independent male and female patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS. 2,4 In the COMPASS study, the Corus CAD test outperformed myocardial perfusion imaging (MPI) as a diagnostic tool to exclude obstructive CAD by demonstrating a higher negative predictive value (96% vs. 88%, p < 0.001) than MPI for assessing the presence of obstructive CAD. 5 To date, over 100,000 Corus CAD test results have been provided to clinicians. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California.

The Corus CAD test has been recognized by The Wall Street Journal 's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME 's Top 10 Medical Breakthroughs.

About CardioDx CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies. Please visit www.cardiodx.com for additional information.

For media inquiries, please contact Glenn Silver of Lazar Partners, +1-212-871-8485, gsilver@lazarpartners.com .

* Obstructive coronary artery disease (CAD) is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or core-lab computerized tomography angiography (CTA)(≥2.0mm lumen diameter).

References

1. Mozaffarian D, Benjamin EJ, Go AS, et al. On Behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2015 Update: A Report from the American Heart Association. Circulation . 2015;131(4):e29-e322. 2. Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet . 2013;6(2):154-162. 3. Ladapo JA, Budoff M, Ross L, et al. Primary Endpoint Results from a Community-Based Registry Evaluating the Use of a Blood-Based Age/Sex/Gene Expression Test in Patients Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease: the PRESET Registry (A Registry to Evaluate Patterns of Care Associated with the Use of Corus ® CAD in Real World Clinical Care Settings). Circ Cardiovasc Qual Outcomes . 2015;8:A142. 4. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med . 2010;153:425-434. 5. The COMPASS study demonstrated that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in a population of men and women referred to MPI.

Glenn Silver Lazar Partners +1-212-871-8485 gsilver@lazarpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 100

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 49

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 65

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading

Top 5 Most Recently Viewed Articles

Latham Plunge Pools Earns Top Honors as Innovative Retail Design

Updated Category News Views 252

Latham Plunge Pools: Celebrating Innovation in Outdoor Living Latham Group, Inc. (NASDAQ:SWIM), the leading designer and manufacturer of in-ground swimming pools, has recently been recognized for its exceptional contribution to the backyard experience. Their latest achievement, the "Most Innovative Product for Retailers" award, was proudly received at the prestigious...

Continue Reading
HF Sinclair Corporation Announces Upcoming Earnings Webcast

Updated Category News Views 120

HF Sinclair Corporation Earnings Announcement HF Sinclair Corporation (NYSE: DINO) is preparing to share its financial results for the third quarter, which ends on September 30, 2024. This important announcement is set for October 31, 2024, and will take place before the market opens on the NYSE. Details of the Earnings Release All investors and interested individuals...

Continue Reading
Verde Resources Unveils VerdePlus, Paving the Way for Green Infrastructure

Updated Category News Views 135

Verde Resources Inc. Introduces VerdePlus for Sustainable Solutions Verde Resources Inc. (OTCQB: VRDR) is proud to announce a transformative step in their efforts towards sustainable infrastructure with the launch of VerdePlus Inc. This innovative subsidiary, developed through a partnership with Nature Plus Inc. (NPI), aims to set new standards in low-carbon construction...

Continue Reading
East Palestine Settlement Center Closure: What You Need to Know

Updated Category News Views 229

Important Closure of the East Palestine Settlement Center The East Palestine Settlement Center, specifically created to aid those affected by a recent train derailment, will be closed on Friday, January 17. This decision comes in response to pending traffic restrictions expected in the surrounding area, which may hinder access to the facility. Rescheduling and Future...

Continue Reading
Aditx Therapeutics Faces Challenges with Stock at $0.18 Low

Updated Category News Views 280

Aditx Therapeutics Faces Significant Stock Decline Aditx Therapeutics Inc (ADTX) has recently encountered a challenging period as its stock price plummeted to a 52-week low of $0.18. This significant decrease illustrates a dramatic 1-year change of -99.9%. Such a downturn highlights the tumultuous state of the biotech company, which is currently grappling with a market...

Continue Reading